Pilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain
March 6th 2025Based on the results of PROGRESS and the previous RELIEF-DPN-1 study, the 10 mg dose of pilavapadin was selected to move forward in clinical development for diabetic peripheral neuropathic pain.
Furthering the Conversation of Treatment Personalization in NMOSD: Tammy Smith, MD, PhD
March 6th 2025The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]
DMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission
March 4th 2025With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.
FDA Approves Expanded Use of Eculizumab for Pediatric Myasthenia Gravis
March 4th 2025Originally approved in 2007, eculizumab (Soliris; Alexion/AstraZeneca) is now available to treat both adult and pediatric patients with generalized myasthenia gravis, becoming the first available option for younger patients with the disease.
Detecting Progression in Multiple Sclerosis With Wearables and Imaging: Jacqueline Nicholas, MD, MPH
March 4th 2025At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]
Phase 4 CLADRINA Data Supports Transition From Natalizumab to Cladribine in Multiple Sclerosis
March 3rd 2025After 24 months after switching to cladribine, 100% of patients with relapsing MS remained free from T1 gadolinium-enhancing lesions, with no reported cases of PML or rebound disease activity.
FDA Approves Tenecteplase for Acute Ischemic Stroke
March 3rd 2025The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, upping the speed and simplicity of the 60-minute infusion of the previously approved alteplase (Activase; Genentech).
A Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed
March 3rd 2025The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]
Recognizing and Investigating the Prodromal Phase in MS and NMOSD: Dalia Rotstein, MD, MPH
March 2nd 2025The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Investigating Immune Cell Signatures in Multiple Sclerosis Progression: Stephanie Zandee, PhD
March 1st 2025At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]
Paving the Way for Autoimmune Neurology Treatment With CAR T-Cell Therapy: Amanda Piquet, MD, FAAN
February 28th 2025The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]